stockrowTaysha Gene Therapies, Inc.
TSHA Healthcare Biotechnology
Taysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024.
- Revenue
- +206.8%
- EPS
- −44.4%
- Free cash flow
- −100.3%
- Total debt
- +20.0%
Quarter to June 2026, against a year earlier
Follow TSHA
Alert me
Taysha Gene Therapies, Inc. (TSHA) EV/Sales
As of 6 November 2026, Taysha Gene Therapies, Inc. (TSHA) trades at a EV/Sales of 102×. Over the past ten years it has ranged from 0.0× (September 2023) to 227× (December 2025); the current reading is higher than 85% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 126× | 211.83% |
| FY2024 | 40.5× | 142.89% |
| FY2023 | 16.7× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 126× | 145.51% |
| Jun 2025 | 51.4× | 23.86% |
| Mar 2025 | 41.5× | 2.54% |
| Dec 2024 | 40.5× | (5.19%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| GHRS GH Research PLC compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| ANAB AnaptysBio, Inc. compare | 4.5× |
| URGN Urogen Pharma compare | 5.4× |
| KRSA Korsana Biosciences, Inc. compare | 8.3× |
| TSHA Taysha Gene Therapies, Inc. | 102× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)